Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

27.79 -0.29 (-1.03%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

17 18 Next >

3 Top-Rated Biotech Stocks Wall Street Analysts Are Loving Now: January 2024 ↗

January 21, 2024

These top-rated biotech stocks are going to be in high demand in January and in every other month in 2024.

Via InvestorPlace

7 Healthcare Stocks Taking Medicine to the Next Level ↗

January 14, 2024

With advances in technology potentially able to improve the human condition, these are the compelling healthcare stocks to consider.

Via InvestorPlace

AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Amylyx Stockholders and Encourages Investors to Contact the Firm

January 06, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

2 Biotech Stocks With Huge Catalysts in 2024 ↗

January 05, 2024

Important clinical-trial readouts on the way could send these stocks soaring in early 2024.

Via The Motley Fool

Earnings Preview For Amylyx Pharma ↗

November 08, 2023

Via Benzinga

Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP)

December 22, 2023

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS

December 04, 2023

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

These biotechs targeting multiple neurodegenerative diseases

December 01, 2023

A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market.

Via MarketBeat

Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 29, 2023

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

3 Top-Rated Biotech Stocks That Analysts Are Loving Now ↗

November 28, 2023

Investing in biotech stocks can be tricky, but analysts have bullish outlooks on these three, promising companies.

Via InvestorPlace

Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer

November 28, 2023

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

RELYVRIO® and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND

November 27, 2023

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Participate at the 6th Annual Evercore ISI HealthCONx Conference

November 21, 2023

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Amylyx Stockholders and Encourages Investors to Contact the Firm

November 15, 2023

From Bragar Eagel & Squire, P.C.

Via Business Wire

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Amylyx Pharmaceuticals, Inc. (AMLX)

November 14, 2023

From Kirby McInerney LLP

Via Business Wire

Why AMC Entertainment Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

November 09, 2023

Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 83.5% to $0.4169 after reporting first-quarter results.

Via Benzinga

Amylyx Crashes 26% As New ALS Drug Faces A Barrage Of Troubles ↗

November 09, 2023

The company says patient discontinuations mounted in the quarter.

Via Investor's Business Daily

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

November 09, 2023

Via Benzinga

Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results

November 09, 2023

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 9, 2023

November 02, 2023

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Present Clinical Trial Design of ORION, a Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy (PSP), at the Neuro2023 PSP and CBD International Research Symposium

October 19, 2023

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

3 Under-the-Radar Biotech Stocks to Buy in 2023 ↗

October 19, 2023

These three lesser-known biotech companies are profitable and growing revenue.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

October 18, 2023

Via Benzinga

Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process

October 13, 2023

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

2 Incredible Growth Stocks Near 52-Week Lows to Buy Now ↗

October 10, 2023

These two high-tech bio companies may be too cheap to ignore right now.

Via The Motley Fool

Amylyx Pharmaceuticals Announces Publication of Survival Analysis Comparing CENTAUR to Historical Clinical Trial Control

October 10, 2023

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Provides Update on Accès Compassionnel for AMX0035 in France

October 05, 2023

From Amylyx Pharmaceuticals

Via Business Wire

RELYVRIO® and AMX0114 Data to be Presented at 22nd Annual Northeast ALS Consortium (NEALS) Meeting

October 02, 2023

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

September 05, 2023

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List ↗

August 28, 2023

Here are some intriguing up-and-coming biotech stocks that may reward risk-tolerant investors with a long-term outlook.

Via InvestorPlace

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.